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rently, there are about 57,500 CAM trials from all over the world 
registered in the Cochrane Central Register of Controlled Trials and 
about 690 systematic CAM reviews in the Cochrane Database. Ber-
man presented a few examples of systematic CAM reviews before 
concluding with future challenges, such as conducting reliable sub-
group analyses (e.g., individual patient data meta-analysis or net-
work meta-analysis) and systematic reviews on complex interven-
tions as well as defining what can be considered as scientifically 
rigorous or relevant to real-world practice of medicine.
Irving Kirsch: ‘Placebo Effects in Complementary and  
Conventional Medicine’
Irving Kirsch, Professor emeritus of medicine at the University 
of Connecticut, University of Hull, Plymouth University, and asso-
ciate director of Placebos Studies and Therapeutic Encounter (PiPS) 
at the Beth Israel Deaconess Medical Center in Harvard Medical 
School provided insights into the most recent research on placebo 
effects in complementary and conventional medicine. He intro-
duced his presentation with the distinction between placebo re-
sponse, which is the general reaction to a placebo, and the placebo 
Background of the Symposium
In January 2014, Claudia Witt became the new director of the 
Institute for Complementary and Integrative Medicine at the Uni-
versity Hospital Zurich, based at the University of Zurich. Decem-
ber 1, 2014 she gave her public inauguration lecture as Chair of the 
institute (fig. 1). On the same day, the institute organized an inter-
national symposium on ‘The Future of Complementary and Inte-
grative Medicine Research’, which took place at the University 
Hospital Zurich. The aim of this half-day symposium was to pro-
vide interdisciplinary and international perspectives, which have 
the potential to bring forward future complementary and integra-
tive medicine research. After the opening speeches by the hospital 
CEO, the vice president of the university, and the dean of the med-
ical school, 7 speakers from 3 countries (UK, USA, and Switzer-
land; fig. 2), including Claudia Witt, provided insights into new re-
search developments in clinical, placebo, and comparative effective-
ness research as well as systems biology. Their presentations can be 
viewed at www.iki.usz.ch/forschung/seiten/praesentationen.aspx.
Symposium Summary
Brian Berman: ‘20 Years of the Cochrane Complementary  
Medicine Field – Where Do We Stand?’
Speaking about ‘20 Years of the Cochrane Complementary Med-
icine Field – Where do we stand?’, Brian Berman, Professor of Fam-
ily and Community Medicine and Coordinator of the Cochrane 
CAM field at the University of Maryland, School of Medicine in 
Baltimore, provided an overview of the history and current state of 
the Cochrane Complementary Medicine Field [1]. The aim of the 
Cochrane Collaboration is preparing, maintaining, and disseminat-
ing systematic reviews on the effects of health care interventions. 
The collaboration consists of 31,000 contributors from more than 
120 countries, 39 Cochrane centers, 53 collaborative review groups, 
10 subfields, 16 method groups, and 1 consumer network. Cur-
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Fig. 1. Claudia M. 
Witt, Chair for Com-
plementary and Inte-
grative Medicine at the 
University of Zurich.
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effect, which corresponds with the effect of a placebo compared to 
usual treatment and to the natural history of a disease. Supported 
by several examples of meta-analyses [e.g., 2, 3] and his own re-
search [e.g. 4], Kirsch showed that both in complementary and con-
ventional medicine the placebo effect as well as the medical treat-
ment effect depend on the condition and on various characteristics 
of the treatment, such as the color of the placebo pill, dose, strength 
of ‘drug’, brand name, price, and therapeutic relationship. To give 
one example: 4 placebo pills a day resulted in a higher response rate 
than 1 placebo pill a day [5]. According to Kirsch, it is therefore 
necessary to examine within-group pre-post changes in both the 
 active treatment and placebo groups as well as report between-
group differences in clinical trials and meta-analyses.
Jürgen Barth: ‘Patient-Doctor-Scientist Interaction: Impact on 
Treatment Outcome’
In his presentation on ‘Patient – Doctor – Scientist Interaction: 
Impact on Treatment Outcome’, Jürgen Barth, Research Director at 
the Institute for Complementary and Integrative Medicine, outlined 
3 perspectives that might influence the outcomes of integrative med-
icine in research and practice. Patient expectations toward treatment 
are an important patient characteristic with an impact on treatment 
outcomes [6], but they do not necessarily match with the expecta-
tions of health professionals [7]. Thus, communication between 
physicians and patients in practice might also contribute to better 
health outcomes, especially if patients perceive the communication 
as helpful [7]. Patient expectations fuelled by health professionals 
might therefore also influence outcomes in placebo research. The 
scientist might also contribute to treatment effects by own expecta-
tions (i.e. allegiance). The allegiance towards a specific treatment 
might bias the research results and overestimate treatment effects 
[8]. Barth concluded that future research should more often use pa-
tient expectations as predictor of treatment response, and that better 
scales are needed for valid assessment. Since good communication 
might result in improved working alliance, a critical evaluation of 
the working alliance during the entire treatment seems necessary. 
Allegiance effects and biases can be lowered by collaborative trials 
and by disclosure statements of scientists and doctors. 
Paul Dieppe: ‘The Evaluation of Health and Wellbeing ‘on 
“wellbeing”’
Paul Dieppe, Professor for Health and Wellbeing at the Medical 
School University of Exeter, shed light on ‘The Evaluation of 
Health and Wellbeing ‘on “wellbeing”, discussing the definition of 
the term, the different approaches to access the topic, and assess-
ment methods used in different disciplines. In this context, Dieppe 
introduced some ideas by the ancient Greeks, contrasting ‘eudai-
monia’ (fulfilling your potential to the benefit of everyone in soci-
ety) and ‘hedonism’ (personal happiness); he pointed out that in 
today’s culture most discussions on wellbeing concentrated on per-
sonal happiness rather than on the benefits of groups or communi-
ties. Many different aspects of our cognitions, emotions, and be-
haviors as well as the environment and circumstances we live in are 
used as basis to assess wellbeing, and several different disciplines 
claim to have suitable assessment methods. According to Dieppe, 
there are 5 different domains entailing wellbeing: mental health, 
physical health, social circumstances, spiritual wellbeing, and pos-
sessions, for which both subjective (self-report) and more objective 
measures are used. Dieppe’s colleagues Myles-Jay Linton and An-
tonieta Medina-Lara are reviewing and classifying all the different 
ways of measuring wellbeing for the benefit of researchers. How-
ever, Dieppe recommended that we need to move from a patho-
logical to a salutogenic understanding of health and wellbeing (the 
generation of health as promoted by Aaron Antonovsky), thereby 
focusing on manageability, meaningfulness, and comprehensibility 
[9, 10]. He concluded that the selected method to evaluate wellbe-
ing should correspond with the research approach, and character-
ized wellbeing as holistic concept entailing body, mind, and spirit.
Jan van der Greef: ‘Bridging Western and Chinese Medicine with 
Systems Biology’
Jan van der Greef, Professor of Analytical Bioscience at Leiden 
University and Principal Scientist at TNO, promoted ‘Bridging 
Western and Chinese Medicine with Systems Biology’, introducing 
a ‘systems view on life’. He stated that more than 90% of drugs only 
work in 30–40% of people in today’s health care. As a result, van 
der Greef suggestd a shift from a ‘one-size fits all’ to ‘personalized’ 
medicine, or, in terms of systems biology, to Western biomarker-
guided medicine supported by the phenomenological approach of 
Chinese Medicine in diagnosis [11–13]. Further, in his opinion it is 
mandatory to apply comparative effectiveness research in real-
world settings. Such an approach implies analyzing complex inter-
dependences of the physical, mental, emotional, social, and spirit-
ual aspects in relation to environmental circumstances of every in-
dividual concerned. Van der Greef concluded that personalized 
medicine must change its focus from symptoms, especially in 
chronic disease to resilience, against the background of social, 
physical, and emotional challenges.
Fig. 2. Speakers of the international symposium ‘The Future of Complementary 
and Integrative Medicine Research’. From left to right: (top) Brian Berman, Irving 
Kirsch, Jürgen Barth; (bottom) Steven Woolf, Jan van der Greef, Paul Dieppe.
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Claudia Witt: ‘Comparative Effectiveness Research (CER) in 
Complementary and Integrative Medicine’
With her presentation of ‘Comparative Effectiveness Research 
(CER) in Complementary and Integrative Medicine’, Claudia 
Witt, Professor of Medicine and Director of the Institute for 
Complementary and Integrative Medicine, provided insights into 
recent developments in a relatively new research field. She fo-
cused on randomized trials and outlined that the eligibility crite-
ria of study participants, the flexibility of the interventions, and 
the type of outcome measures are key criteria to distinguish be-
tween randomized controlled trials providing information on the 
efficacy of a treatment (evidence from ideal study settings) and 
randomized pragmatic trials providing evidence on the effective-
ness of an intervention (evidence from a usual care study setting). 
Witt showed that acupuncture research has already made unique 
contributions to comparative effectiveness research (CER) [14] by 
developing guiding recommendations [15, 16]. The most recent 
recommendations even try to close the gap between CER and 
‘omics’.
Steven Woolf: ‘The Impact of Stakeholder Engagement – Lessons 
Learned from Health Services and Public Health Research’
Steven Woolf, Professor of Family Medicine and Director of the 
VCU Center on Society and Health at Virginia Commonwealth 
University in Richmond, gave a lecture on ‘The Impact of Stake-
holder Engagement – Lessons Learned from Health Services and 
Public Health Research’. He presented 2 research projects involv-
ing stakeholder engagement that had been conducted by his insti-
tution [17].
He first noted the emergence of an international trend in health 
research that emphasizes deeper engagement of the ‘affected party.’ 
In clinical research, this includes an emphasis on shared decision-
making and patient-centered outcome research. A hallmark of this 
approach is a commitment to stakeholder engagement at every 
stage of a research project. Woolf described in detail the process of 
patient engagement that was undertaken in a pilot study on how 
patients approach decisions about cancer screening. A second ex-
ample involved community engagement, in which residents of a 
community in the East End of Richmond helped set population 
health priorities and developed new causal models about the role of 
social determinants of health.
Woolf concluded that stakeholder engagement means first of all 
forging a coequal partnership and a transition from research sub-
jects to co-investigators.
Conclusion
There is already a decent amount of clinical research on com-
plementary and integrative medicine. However, the discussion 
made clear that the bio-psychosocial understanding of and ap-
proach to disease in complementary and integrative medicine goes 
along with a large amount of complexity that has to be considered 
when designing future trials. Recent research on placebo as well as 
new approaches, such as systems biology and CER, could be help-
ful to guide future research.
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